Glycaemic control in newly diagnosed diabetes patients and mortality from ischaemic heart disease: 20-year follow-up of the HUNT Study in Norway

European Heart Journal

Volumn 30, Issue 11, 2009, Pages 1372-1377

  Dale, Ane Cecilie ^a,b   Midthjell, Kristian ^a   Nilsen, Tom Ivar ^a   Wiseth, Rune ^a,b   Vatten, Lars J ^a,c  

^a NORWEGIAN UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Norway)

^b TRONDHEIM UNIVERSITY HOSPITAL   (Norway)

^c INTERNATIONAL AGENCY FOR RESEARCH ON CANCER   (France)

Author keywords

Diabetes mellitus; Follow up; Glycaemic control; Ischemic heart diseases; Mortality

Indexed keywords

GLUCOSE; HEMOGLOBIN A1C; GLYCOSYLATED HEMOGLOBIN;

ADULT; AGED; ARTICLE; DISEASE ASSOCIATION; FEMALE; FOLLOW UP; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HUMAN; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; NORWAY; ORAL GLUCOSE TOLERANCE TEST; PRIORITY JOURNAL; COHORT ANALYSIS; DIABETES MELLITUS; DIABETIC ANGIOPATHY; HEART MUSCLE ISCHEMIA; LIFESTYLE; RISK ASSESSMENT; SEX DIFFERENCE;

AGED; COHORT STUDIES; DIABETES MELLITUS; DIABETIC ANGIOPATHIES; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; LIFE STYLE; MALE; MYOCARDIAL ISCHEMIA; NORWAY; RISK ASSESSMENT; SEX FACTORS;

EID: 67651089956     PISSN: 0195668X     EISSN: 15229645     Source Type: Journal    
DOI: 10.1093/eurheartj/ehp039     Document Type: Article

References (38)

1. Harris Ml, Klein R, Welborn TA, Knuiman MW. Onset of NIDDM occurs at least 4-7 yr before clinical diagnosis. Diabetes Care 1992; 15:815-819.
2. Haffner SM, Stern MP, Hazuda HP, Mitchell BD, Patterson JK. Cardiovascular risk factors in confirmed prediabetic individuals. Does the clock for coronary heart disease start ticking before the onset of clinical diabetes? JAMA 1990; 263: 2893-2898.
3. Ryden L, Standi E, Bartnik M et al. Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: executive summary. The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD). Eur Heart] 2007; 28: 88-136.
4. Tuomilehto J, Lindström J, Eriksson JG, Valle TT, Hämäläinen H, llanne-Parikka P, Keinänen-Kiukaanniemi S, Laakso M, Louheranta A, Rastas M, Salminen V, Uusitupa M. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med 2001; 344: 1343-1350.
5. Knowler WC, Barrett-Connor E, Fowler SE, Hamman RF, Lachin JM, Walker EA, Nathan DM. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002; 346:393-403.
6. Vilbergsson S, Sigurdsson G, Sigvaldason H, Sigfusson N. Coronary heart disease mortality amongst non-insulin-dependent diabetic subjects in Iceland: the independent effect of diabetes. The Reykjavik Study 17-year follow up. J Intern Med 1998; 244:309-316.
7. Fox CS, Sullivan L, D'Agostino RB Sr, Wilson PW. The significant effect of diabetes duration on coronary heart disease mortality: the Framingham Heart Study. Diabetes Care 2004; 27:704-708.
8. Stamler J, Vaccaro O, Neaton JD, Wentworth D. Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. Diabetes Care 1993; 16:434-444.
9. Cho E, Rimm EB, Stampfer MJ, Willett WC, Hu FB. The impact of diabetes mellitus and prior myocardial infarction on mortality from all causes and from coronary heart disease in men. J Am Coll Cardiol 2002; 40:954-960.
10. Dale AC, Nilsen Tl, Vatten L, Midthjell K, Wiseth R. Diabetes mellitus and risk of fatal ischaemic heart disease by gender: 18 years follow-up of 74 914 individuals in the HUNT 1 Study. Eur Heart J 2007; 28:2924-2929.
11. The DECODE Study Group on behalf of the European Diabetes Epidemiology Group. Is the current definition for diabetes relevant to mortality risk from all causes and cardiovascular and non cardiovascular diseases? Diabetes Care 2003; 26:688-696.
12. Uusitupa Ml, Niskanen LK, Sntonen O, Voutilainen E, Pyörä lä K. Ten-year cardiovascular mortality in relation to risk factors and abnormalities in lipoprotein composition in type 2 (non-insulin-dependent) diabetic and non-diabetic subjects. Diabetologia 1993; 36:1175-1184.
13. Bartnik M, Malmberg K, Norhammar A, Tenerz A, Ohrvik J, Ryden L Newly detected abnormal glucose tolerance: an important predictor of long-term outcome after myocardial infarction. Eur Heart J 2004; 25:1990-1997.
14. Bartnik M, Malmberg K, Hamsten A, Nilsson G, Ryden L. Abnormal glucose tolerance - a common risk factor in patients with acute myocardial infarction in comparison with population-based controls. J Intern Med 2004; 256:288-297.
15. Hu FB, Stampfer MJ, Haffner SM, Solomon CG, Willett WC, Manson JE. Elevated risk of cardiovascular disease prior to clinical diagnosis of type 2 diabetes. Diabetes Care 2002; 25:1129-1134.
16. Clark CM, Perry RC. Type 2 diabetes and macrovascular disease: epidemiology and etiology. Am Heart J 1999; 138:S330-S333.
17. Stratton IM, Adler AI, Neil HA, Matthews DR, Manley SE, Cull CA, Hadden D, Turner RC, Holman RR. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 2000; 321:405-412.
18. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998; 352: 837-853.
19. Coutinho M, Gerstein HC, Wang Y, Yusuf S. The relationship between glucose and incident cardiovascular events. A metaregression analysis of published data from 20 studies of 95,783 individuals followed for 12.4 years. Diabetes Care 1999; 22:233-240.
20. Wei M, Gaskill SP, Haffner SM, Stern MP. Effects of diabetes and level of glycemia on all-cause and cardiovascular mortality. The San Antonio Heart Study. Diabetes Care 1998; 21:1167-1172.
21. Stevens RJ, Coleman RL, Adler AI, Stratton IM, Matthews DR, Holman RR. Risk factors for myocardial infarction case fatality and stroke case fatality in type 2 diabetes: UKPDS 66. Diabetes Care 2004; 27:201-207.
22. Malmberg K, Norhammar A, Wedel H, Ryden L Glycometabolic state at admission: important risk marker of mortality in conventionally treated patients with diabetes mellitus and acute myocardial infarction: long-term results from the Diabetes and Insulin-Glucose Infusion in Acute Myocardial Infarction (DIGAMI) study. Circulation 1999; 99:2626-2632.
23. Malmberg K, Rydén L, Wedel H, Birkeland K, Bootsma A, Dickstein K, Efendic S, Fisher M, Hamsten A, Herlitz J, Hildebrandt P, MacLeod K, Laakso M, Torp-Pedersen C, Waldenström A. Intense metabolic control by means of insulin in patients with diabetes mellitus and acute myocardial infarction (DIGAMI 2): effects on mortality and morbidity. Eur Heart J 2005; 26:650-661.
24. Andersson DK, Svärdsudd K. Long-term glycémic control relates to mortality in type II diabetes. Diabetes Care 1995; 18:1534-1543.
25. Malmberg K, Rydén L, Efendic S, Herlitz J, Nicol P, Waldenström A, Wedel H, Welin L. Randomized trial of insulin-glucose infusion followed by subcutaneous insulin treatment in diabetic patients with acute myocardial infarction (DIGAMI study): effects on mortality at 1 year. J Am Coll Cardiol 1995; 26:57-65.
26. Knatterud GL, Klimt CR, Levin ME, Jacobson ME, Goldner MG. Effects of hypoglycemic agents on vascular complications in patients with adult-onset diabetes. VII. Mortality and selected nonfatal events with insulin treatment. JAMA 1978; 240:37-42.
27. Holmen J, Midthjell K, Bjartveit K, Hjort PF, Lund-Larsen PG, Mourn T, Næss S, Waaler HT. The North-Trøndelag Health Survey 1984-86. Purpose, background and methods. Participation, non-participation and frequency distribution. Report no. 4. Statens Institutt for Folkehelse, Senter for Samfunnsmedisinsk Forskning, 1990.
28. WHO Expert Committee on Diabetes Mellitus, Second report. World Health Organ Tech Rep Ser 1980; 646:1-80.
29. Passing H, Bablok W. A new biometrical procedure for testing the equality of measurements from two different analytical methods. Application of linear regression procedures for method comparison studies in clinical chemistry, Part I. J Clin Chem Clin Biochem 1983; 21:709-720.
30. Bonora E, Muggeo M. Postprandial blood glucose as a risk factor for cardiovascular disease in Type II diabetes: the epidemiological evidence. Diabetologia 2001; 44: 2107-2114.
31. Laakso M, Kuusisto J. Epidemiological evidence for the association of hyperglycae-mia and atherosclerotic vascular disease in non-insulin-dependent diabetes mellitus. Ann Med 1996; 28:415-418.
32. Ravipati G, Aronow WS, Ahn C, Sujata K, Saulle LN, Weiss MB. Association of hemoglobin A(1 c) level with the severity of coronary artery disease in patients with diabetes mellitus. Am J Cardiol 2006; 97:968-969.
33. Abaci A, Oguzhan A, Kahraman S, Eryol NK, Unal S, Arinç H, Ergin A. Effect of diabetes mellitus on formation of coronary collateral vessels. Circulation 1999; 99:2239-2242.
34. Balkau B, Shipley M, Jarrett RJ et al. High blood glucose concentration is a risk factor for mortality in middle-aged nondiabetic men. 20-year follow-up in the Whitehall Study, the Paris Prospective Study, and the Helsinki Policemen Study. Diabetes Care 1998; 21:360-367.
35. Stettler C, Allemann S, Juni P, Cull CA, Holman RR, Egger M, Krähenbühl S, Diem P. Glycémie control and macrovascular disease in types 1 and 2 diabetes mellitus: Meta-analysis of randomized trials. Am Heart J 2006; 152:27-38.
36. Nathan DM, Cleary PA, Backlund JY, Genuth SM, Lachin JM, Orchard TJ, Raskin P, Zinman B. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med 2005; 353:2643-2653.
37. Hu FB, Stampfer MJ, Solomon CG, Liu S, Willett WC, Speizer FE, Nathan DM, Manson JE. The impact of diabetes mellitus on mortality from all causes and coronary heart disease in women: 20 years of follow-up. Arch Intern Med 2001; 161: 1717-1723.
38. Brun E, Nelson RG, Bennett PH, Imperatore G, Zoppini G, Verlato G, Muggeo M. Diabetes duration and cause-specific mortality in the Verona Diabetes Study. Diabetes Care 2000; 23:1119-1123.